Siplizumab

(sip-LIH-zoo-mab) A substance being studied in the treatment of certain types of T-cell lymphoma. It is also being studied in the prevention of organ or tissue rejection after a kidney and/or bone marrow transplant. Siplizumab binds to a protein called CD2, which is found on some types of immune cells and cancer cells. This may help suppress the body’s immune response and it may help kill cancer cells. Siplizumab is a type of monoclonal antibody. Also called MEDI-507.

• Dailymed label info on Siplizumab
• FDA Siplizumab

Siplizumab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski